<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03757351</url>
  </required_header>
  <id_info>
    <org_study_id>TDR16536</org_study_id>
    <secondary_id>DNLI-D-0003</secondary_id>
    <nct_id>NCT03757351</nct_id>
  </id_info>
  <brief_title>Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis</brief_title>
  <official_title>A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL747 in Subjects With Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Denali Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and
      pharmacodynamics of multiple oral doses of DNL747 in subjects with Amyotrophic Lateral
      Sclerosis in a cross-over design
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to change in Sanofi's development strategy for DNL747/SAR443060 - not due to any safety
    concerns
  </why_stopped>
  <start_date type="Actual">December 28, 2018</start_date>
  <completion_date type="Actual">June 18, 2020</completion_date>
  <primary_completion_date type="Actual">March 12, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects with Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Randomization - Day 86</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects with clinically significant neurological examination abnormalities</measure>
    <time_frame>Randomization - Day 86</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects with laboratory test abnormalities</measure>
    <time_frame>Randomization - Day 86</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic measure of maximum observed plasma concentration (Cmax) of DNL747</measure>
    <time_frame>Randomization - Day 86</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic measure of time to reach maximum observed plasma concentration (Tmax) of DNL747</measure>
    <time_frame>Randomization - Day 86</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic measure of area under the plasma drug concentration-time curve (AUC) of DNL747</measure>
    <time_frame>Randomization - Day 86</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic terminal disposition rate constant (λz) with the respective t1/2 of DNL747</measure>
    <time_frame>Randomization - Day 86</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic measure of CSF concentrations of DNL747</measure>
    <time_frame>Randomization - Day 86</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic measure of pS166 in PBMCs</measure>
    <time_frame>Randomization - Day 86</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>DNL747 First, Placebo Second</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo First, DNL747 Second</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Open-Label Extension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conducted in the Netherlands only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DNL747</intervention_name>
    <description>Repeating oral dose</description>
    <arm_group_label>DNL747 First, Placebo Second</arm_group_label>
    <arm_group_label>Open-Label Extension</arm_group_label>
    <arm_group_label>Placebo First, DNL747 Second</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Repeating oral dose</description>
    <arm_group_label>DNL747 First, Placebo Second</arm_group_label>
    <arm_group_label>Placebo First, DNL747 Second</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria (Double-Blind Part):

          -  Women of non-childbearing potential and men, aged 21−80 years

          -  Willingness and ability to complete all aspects of the study; participant should be
             capable of completing assessments either alone or with help of a caregiver

          -  Diagnosis of laboratory-supported probable, probable, or definite (sporadic or
             familial) ALS according to the El Escorial World Federation of Neurology revised
             research diagnostic criteria

          -  Less than 3 years since symptom onset

          -  Forced vital capacity (FVC) &gt;50% predicted measured within 30 days of screening

          -  If subject is taking approved ALS treatments (riluzole and/or edaravone), doses must
             be stable for ≥2 months prior to screening and subject is expected to stay on a stable
             regimen throughout the study

        Key Exclusion Criteria (Double-Blind Part):

          -  History of a clinically significant non-ALS neurologic disorder (other than frontal
             temporal lobe dementia), including, but not limited to, muscular dystrophy, spinal
             stenosis, peripheral neuropathy, inherited neuropathies, AD, Parkinson's disease, Lewy
             body dementia, vascular dementia, Huntington's disease, epilepsy, stroke, multiple
             sclerosis, brain tumor, or brain infection or abscess

          -  Unstable or poorly controlled comorbid disease process of any organ system currently
             requiring active treatment or likely to require treatment adjustment during the study

        Key Inclusion Criteria (Open-Label Extension):

          -  Successful completion of both periods of the the double-blind, crossover part of the
             study

          -  Continued diagnosis of laboratory-supported probable, probable, or definite (sporadic
             or familial) ALS according to the El Escorial World Federation of Neurology revised
             research diagnostic criteria

        Key Exclusion Criteria (Open-Label Extension):

          -  Presence of laboratory abnormalities, physical examination findings, or AEs determined
             to be clinically significant by the investigator from the double-blind part of the
             study that have not resolved by the final follow-up visit as part of the double-blind
             study period

          -  New diagnosis of clinically significant neurological disorder (other than frontal
             temporal lobe dementia)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bioclinica</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHDR</name>
      <address>
        <city>Leiden</city>
        <state>South Holland</state>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 27, 2018</study_first_submitted>
  <study_first_submitted_qc>November 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2018</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

